Radiopharmaceutical-Related pitfalls and artifacts

Seminars in Nuclear Medicine

Volumn 26, Issue 4, 1996, Pages 208-255

  Hung, Joseph C ^a   Ponto, James A ^b   Hammes, Richard J ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT; TECHNETIUM;

ARTIFACT; HUMAN; REVIEW; SCINTISCANNING;

ARTIFACTS; HUMANS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TECHNETIUM;

EID: 0030256299     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-2998(96)80002-x     Document Type: Article

References (465)

1. Hladik WB, Ponto JA, Lentle BC, et al: latrogenic alterations in the biodistribution of radiotracers as a result of drug therapy: Reported instances, in Hladik WB, Saha GB, Study KT (eds): Essentials of Nuclear Medicine Science. Baltimore, MD, Williams & Wilkins, 1987, pp 189-219
2. Lentle BC, Styles CB: latrogenic alterations in the biodistribution of radiotracers as a result of radiation therapy, surgery, and other invasive medical procedures, in Hladik WB, Saha GB, Study KT (eds): Essential of Nuclear Medicine Science. Baltimore, MD, Williams & Wilkins, 1987, pp 220-233
3. Coupai JJ, Kim EE: Normal clinical variation in anatomic structure and physiologic function and its effect on radiopharmaceutical biodistribution, in Hladik WB, Saha GB, Study KT (eds): Essentials of Nuclear Medicine Science. Baltimore, MD, Williams & Wilkins, 1987, pp 234-247
4. Kirn EE, Coupai JJ: Unusual or unanticipated alterations in the biodistribution of radiopharmaceuticals as a result of pathologic mechanisms, in Hladik WB, Saha GB, Study KT (eds): Essential of Nuclear Medicine Science. Baltimore, MD, Williams & Wilkins, 1987, pp 248-267
5. Ponto JA, Swanson DP, Freitas JE: Clinical manifestations of radiopharmaceutical formulation problems, in Hladik WB, Saha GB, Study KT (eds): Essentials of Nuclear Medicine Science. Baltimore, MD, Williams & Wilkins, 1987, pp 268-289
6. Ponto JA: A review of radiopharmaceutical formulation problems and their clinical manifestations, in Hladik WB (ed): Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals. Albuquerque, NM, University of New Mexico, 1993, pp 1-45
7. Hojelse C, Kristensen K, Sampson CB: Factors which affect the integrity of radiopharmaceuticals, in Sampson CB (ed): Textbook of Radiopharmacy-Theory and Practice. Langhorne, PA, Gordon and Breach, 1994, pp 145-151
8. Neirinckx RD, Canning LR, Piper IM, et al: Technetium-99m rf,/-HM-PAO: A new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 28:191-202, 1987
9. Bannister KM, Penglis S, Bellen JC, et al: Kit preparation of technetium-99m-mercaptoacetyltriglycine: Analysis, biodistribution and comparison with technelium-99mDTPA in patients with impaired renal function. J Nucl Med 31:1568-1573, 1990
10. Lewis SE, Buja LM, Dehmer GJ, et al: Nuclear Cardiology-1980. Kalamazoo, MI, Upjohn, 1979, pp 20-23
11. Lecklitner ML, Benedetto AT, Straw JD: Failure of quality control to detect errors in the preparation of technetium-99mdisofenin (DISIDA). Clin Nucl Med 10:468474. 1985
12. Hupp BD, Nagel MV, Augustine S: Unit dose radiochemical stability of commonly used technetium-99m radiopharmaceuticals. J Nucl Med Technol 14:202-205, 1986
13. Tatum JL, Burke TS, Hirsch JI, et al: Artifactual focal accumulation of Tc-99m bone imaging tracer in the chest. Clin Nucl Med 10:16-18, 1985
14. Hammes RJ, Rowe BR, Deborah MA, el al: Quality control of Tc-99m DTPA used for GFR studies. J Nucl Med 29:980, 1988(abstr)
15. Russell CD, Rowell K, Scott JW: Quality control of technetium-99m DTPA: Correlation of analytic tests with in vivo protein binding in man. J Nucl Med 27:560-562,1986
16. Shih WJ, Coupai JJ, Donstad PA, et al: Diffuse thoracoabdominal radioactivity seen in bone imaging. Clin Nucl Med 11:254-258,1986
17. 4 carrier-free? J Nucl Med 16:639-641, 1975
18. Molter M: The current status of WmTc generators. Nuklearmedizin 20:7-10, 1981
19. Albers JW, Jenkins D, Sandee RJ, et al: Free (unreacted) pertechnetate in technetium-sulfur colloid preparations. J Nucl Med Technol 2:14-17, 1974
20. Hambright P, McRae J, Valk PE, et al: Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier wTc. J Nucl Med 16:478-482, 1975
21. Porter WV. Dworkin HJ, Gutkowski RF: The effect of carrier technetium in the preparation of WmTc-human serum albumin. J Nucl Med 17:704-706, 1976
22. Maughan J, Riley A, Parkin A: Poor binding efficiency using ''TV-labeled HSA. Nucl Med Commun 11:720722, 1990 (letter)
23. Smith TD, Steimers JR, Richards P: Chemical effect of Tc on WmTc labeled radiopharmaceuticals. J Nucl Med 16:570-571, 1975 (abstr)
24. 99mTc-labeled red blood cells. J Nucl Med 17:126131,1976
25. Porter WC, Dees SM, Freitas JE, et al: Acid-citratedextrose compared with heparin in the preparation of in vivo/in vitro technetium-99m red blood cells. J Nucl Med 24:383-387, 1983
26. Wilson ME, Hung JC: Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag RBC kit. J Nucl Med 33:306-307, 1992 (letter)
27. Srivastava SC. Sträub RF: Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag15 RBC kit-Reply. J Nucl Med 33:307-308, 1992 (letter)
28. Wolfangel RG: Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99mred blood cells with UltraTagRBC kit-Reply. J Nucl Med 33:308, 1992 (letter)
29. Kelly MJ. Cowie A, Antonino A, et al: An assessment of factors which influence the effectiveness of the modified in vivo erythrocyte labeling technique. J Nucl Med 32:1090, 1991 (abstr)
30. Kelly MJ, Cowie AR, Antonino A, et al: An assessment of factors which influence the effectiveness of the modified in vivo technetium-99m-erythrocyte labeling technique in clinical use. J Nucl Med 33:2222-2225, 1992
31. Wolfangel RG, Srivastava SC, Bushman MJ, et al: UltraTag RBC kit-Relationship between anticoagulants and reagent volume on RBC labeling efficiency and kinetics. J Nucl Med 33:989, 1992 (abstr)
32. Hung JC, Wilson ME: Optimum concentration of ACD in the preparation of technetium-99m red blood cells with the UltraTag RBC kit. J Nucl Med Technol 20:107, 1992 (abstr)
33. Brandau W, Schober O, Knapp WH: Determination of brain death with technetium-99m-HMPAO. J Nucl Med 31:2075-2076,1990 (letter)
34. Gagnon A, Leveille J, Bavaria G, et al: Labelling efficiency analysis of 99mTc-HMPAO: Comparison between standard elution and multiple elution method. J Nucl Med 32:1103,1991 (abstr)
35. Piera C, Martinez A, Ramirez I: Radiochemical purity of technetium-99m-HMPAO depends on specific activity. J Nucl Med 36:706,1995
36. 99mTc-labeling efficiency. Nuklearmedizin 16:271-274,1977
37. Decristoforo C, Chen F, Stoger A, et al: Failure of labeling of anti-granulocyte antibody. Eur J Nucl Med 20:565-566,1993
38. Nosco DL, Wolfangel RG, Bushman MJ, et al: Technetium-99m MAGs: Labeling conditions and quality control. J Nucl Med Technol 21:69-74,1993
39. m-MAG3. Nucl Med Commun 16:157-160,1995
40. Herold TJ, Wilson ME, Hung JC, et al: Generator eluate effects on the labeling efficiency of Tc-99m sestamibi kits. J Nucl Med 34:148P, 1993
41. 99mTc] HMPAO images. J Nucl Med 31:118-122,1990
42. Bayne VJ, Forster AM, Tyrrell DA: Use of sodium iodide to overcome the eluate age restriction for Ceretec® reconstitution. Nucl Med Commun 10:29-33,1989
43. m-exametazime. Nucl Med Commun 13:306-311,1992
44. Millar AM: Effect of source and age of sodium pertechnetate Tc99m on radiochemical purity of technetium Tc 99m exametazime. Am J Hosp Pharm 50:103-106, 993
45. Van Duzee BF, Bugaj JE. The effect of total technetium concentration on the performance of a skeletal imaging agent [abstractJ. Clin Nucl Med 6:P148, 1981 (suppl; abstr)
46. Szlaczky LA, Latino FA, Payne SE, et al: The hepatobiliary excretion of Tc-99m MAG3. J Nucl Med 33:990, 1992 (abstr)
47. Thorson LM, Hung JC, Hollar BS: Feasibility of fractionating MAG3 cold kit for cost reduction. Nucl Med Commun 13:832-837,1992
48. Ballinger J: Preparation of technetium-99m-HMPAO. J Nucl Med 31:1892,1990 (letter)
49. Tubergen K, Corlija M, Volkert WA, et al: Sensitivity of technetium-99m-d,/-HMPAO to radiolysis in aqueous solutions. J Nucl Med 32:111-115,1991
50. 99mTc-d,1-HMPAO in aqueous solutions. J Nucl Med 31:806, 1990 (abstr)
51. Lang J, Barbaries E, Lazar J, et al: Effects of labeling conditions and formulation of kit on in vitro stability of 99m-Tc-uf,/-HM-PAO. Eur J Nucl Med 15:424, 1989 (abstr)
52. 99mTc-sulfur colloid-Evaluation of preparation parameters for kits from four commercial manufacturers, in Sorenson JA: Radiopharmaceuticals II: Proceedings of the 2nd International Symposium on Radiopharmaceuticals: March 19-22, 1979, Seattle. New York, NY, Society of Nuclear Medicine, 1979, pp 15-23
53. Krishnamurthy GT, Tubis M, Joe P, et al: Clinical assessment of the importance of the quantity of tin in commercial bone imaging kits. J Nucl Med 19:565-567,1978 (letter)
54. Francis MD, Tofe AJ, Hues RA, et al: Inorganic tin: chemistry, disposition and role in nuclear medicine diagnostic skeletal imaging agents. Int J Nucl Med Bio'1 8:145-152, 1981
55. Subramanian G, McAfee JF: Stannous oxide colloid labeled with 99mTc or 113mln for bone marrow imaging. J Nucl Med 11:365-366,1970
56. Bardy A, Fouye H, Gobin R, et al: Technetium-99m labeling by means of stannous pyrophosphate: Application to bleomycin and red blood cells. J Nucl Med 16:435-437, 1975
57. Zimmer AM: In vitro technetium-99m red blood cell labeling using commercial stannous pyrophosphate. Am J Hosp Pharm 34:264-267,1977
58. Callahan RJ, Froelich JW, McKusick KA, et al: Factors affecting the rate and extent of incorporation of 99mTc into pre-tinned red blood cells (RBC). J Nucl Med 23:P109,1982 (abstr)
59. Zanelli GD: Effect of certain drugs used in the treatment of cardiovascular disease on the quot;in vitroquot; labeling of red blood cells with Te. Nucl Med Commun 3:155-161,1982
60. Zimmer AM, Pavel DG, Karesh SM: Technical parameters of in vivo red blood cell labeling with technetium99m. Nuklearmedizin 18:241-246,1979
61. Feldkamp M, Spicer J: Problems with technetium99m-red blood cell labeling. J Nucl Med Technol 19:50, 1991 (letter)
62. m using whole blood. Nucl Med Commun 12:461-464,1991
63. Srivastava SC, Chervu LR: Radionuclide-labeled red blood cells: current status and future prospects. Semin Nucl Med 14:68-82,1984
64. Hamilton RG, Alderson PO: A comparative evaluation of techniques for rapid and efficient in vivo labeling of red cells with [99mTc] pertechnetate. J Nucl Med 18:10081011,1977
65. 99mTc tin (II) pyrophosphate kits. Am J Hosp Pharm 38:1722-1726,1981
66. Tofe AJ, Bevan JA, Fawzi MB, et al: Antioxidant stabilization of bone agents, in Sorenson JA: Radiopharmaceuticals II: Proceedings of the 2nd International Symposium on Radiopharmaceuticals: March 19-22,1979, Seattle. New York, NY, Society of Nuclear Medicine, 1979, pp 637-644
67. 99mTc(Sn)HMDP. Nucl Med Biol 14:37-41, 1987
68. Yano Y, McRae J, Van Dyke DC, et al: Technetium-99m-labeled stannous ethane-a-hydroxy-l,l-diphosphonate: A new bone scanning agent. J Nucl Med 14:73-78, 973
69. 99mTc-pertechnetate. J Nucl Med 15:69-74, 974
70. McKusick KA, Malmud LS, Kirchner PT, et al: An interesting artifact in radionuclide imaging of the kidneys. J Nucl Med 14:113-114,1973
71. Robins PJ, Williams CC: An investigation of low tagging yields of 99mTc DTPA kits. J Nucl Med 20:653, 1979 (abstr)
72. Afshan A, Jehangir M, Ashraf M, et al: Formulation of a single-component kit for the preparation of technetium99m labelled ethyl cysteinate dimer: biological and clinical evaluation. Eur J Nucl Med 21:991-995,1994
73. Green JM, Donohoe ME, Foster ME, et al: Thin layer Chromatographie procedures for the characterization of technetium-99m bicisate. J Nucl Med Technol 22:21-26, 1994
74. McBride MHD, Shaw SM, Kessler WV: Deterioration of stannous ion in radiopharmaceutical kits during storage. Am J Hosp Pharm 36:1370-1372,1979
75. Owunwanne A, Church LB, Blau M: Effect of oxygen on the reduction of pertechnetate by stannous ion. J Nucl Med 18:822-826,1977
76. Majewski W, Zimmer AM, Spies SM: Stannous-tin levels in commercial stannous pyrophosphate: effect of altering preparation methods [abstractJ. J Nucl Med Technol 9:116,1981
77. Fleming WK, Jay M, Ryo UY: Reconstitution and fractionation of radiopharmaceutical kits [letterJ. J Nucl Med 33:1915,1992
78. 99mTc-radiopharmaceutical kits. Eur J Nucl Med 7:291-293,1982
79. Cheng KT, Spiker KM, Gordon L: The preparation parameters of technetium-99m-macroaggregated albuminlow particle number. J Nucl Med Technol 22:173-177, 1994
80. Adalet I, Cantez S: Poor-quality red blood cell labelling with technetium-99m: case report and review of the literature. Eur J Nucl Med 21:173-175,1994
81. Solanki C, Li DJ, Wong A, et al: Stabilization and multidose use of exametazime for cerebral perfusion studies. Nucl Med Commun 15:718-722,1994
82. Hawkins T, Reeder A, Keavey PM, et al: The long-term stability of reconstituted exametazime: a clinical and laboratory evaluation. Nucl Med Commun 12:1045-1055,1991
83. Tikofsky RS, Trembath LA, Voslar AM: Radiophar-maceuticals for brain imaging: the technologist's perspective. J Nucl Med Technol 21:57-60,1993
84. Billinghurst MW, Rempel S, Westendorf BA: Radiation decomposition of Tc radiopharmaceuticals. J Nucl Med 20:138-143,1979
85. Zimmer AM, Pavel DG: Experimental investigations of the possible cause of liver appearance during bone scanning. Radiology 126:813-816,1978
86. McCormick MV, Sinclair MD, Wahner HW: Chromatographie quality of three 99mTc bone-imaging agents. J Nucl Med Technol 4:189-192,1976
87. 99mTc-labeled red blood cells. J Nucl Med 12:310-311,1971
88. Hung JC, Corlija M, Volkert WA, et al: Kinetic analysis of technetium-99m d,/-HM-PAO decomposition in aqueous media. J Nucl Med 29:1568-1576,1988
89. Ramamoorthy N, Pillai MRA, Troutner DE: Studies on some aspects of the instability of Tc-hexamethylpropylene amine oxime (Tc-HMPAO). Nucl Med Biol 20:307-310, 1993
90. Solanki C, Li DJ, Wong A, et al: Multidose use of exametazime for leukocyte labelling: A new approach using tin enhancement. Nucl Med Commun 14:1035-1040,1993
91. Gouaillardouu D, Conti ML: The influence of the charge and of the tin-ligand ratio on bone uptake of technetium 99m labelled osteotropic radiopharmaceuticals. Appl Radiât Isot 38:103-106,1987
92. van den Brand JAGM, Das HA, Dekker BG, et al: The influence of the method of preparation of the bone scanning agent 99mTc(Sn)EHDP on its tissue distribution in the rat. Int J Appl Radiât Isot 33:917-928,1982
93. 99mTc-methylene diphosphonate. Nuklearmedizin 21:150-156,1982
94. Bugaj JE, De Rosch MA, Marmion ME, et al: Novel chemistry used in the cyclodextrin-stabilized TechneScan(R) Q,2 kit. J Nucl Med 35:139P, 1994
95. 99mTe dimercaptosuccinate complexes and their evaluation as radiotracers. J Nucl Med 18:1222-1229,1977
96. Nunn AD, Schramm E: Analysis of Tc-HIDAs and factors affecting their labeling rate, purity, and stability. J Nucl Med 2:P52,1981 (abstr)
97. Gerson B, Ballinger JR, Gulenchyn KY: Improved modification for in vitro labeling of red blood cells with technetium-99m. J Nucl Med Technol 16:9-11,1988
98. Danpure HJ, Osman S, Carroll MJ, et al: In vitro studies to develop a clinical protocol for radiolabeling mixed leukocytes with Tc-99m HMPAO. J Nucl Med 28:694,1987 (abstr)
99. Vanlic-Razumenic N, Pujic N, Dedovic N, et al: Labelling of leukocytes with 99mTc-HMPAO for scintigraphy of inflammatory lesions and abscesses. Nucl Med Biol 19:251-256,1992
100. 99mTc-HMPAO. Nucl Med Biol 17:443,1990
101. 99mTc. Eur J Nucl Med 16:299-302, 1990
102. m-HMPAO). Nucl Med Commun 9:267-272, 1988
103. m hexametazimelabeled leucocytes. Nucl Med Commun 9:753-761, 1988
104. m-exametazime-labelled leukocytes: Effect of volume and concentration of exametazime on labelling efficiency, and clinical protocol for high efficiency multi-dose radiolabeling. Nucl Med Commun 12:719-723, 1991
105. Babich JW, Solomon H, Pike MC, et al: Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogues for imaging focal sites of bacterial infection. J Nucl Med 34:1964-1974, 1993
106. Millar AM, O'Brien: An investigation of factors that might influence the radiochemical purity and stability of Tc-MAG3. Eur J Nucl Med 16:615-619, 1990
107. Shattuck LA, Eshima D, Taylor AT, et al: Evaluation of the hepatobiliary excretion of technetium-99m-MAG3 and reconstitution factors affecting radiochemical purity. J Nucl Med 35:349-355, 1994
108. 99mgmTc-HMPAO)-labeled white blood cells: A high efficiency multidose procedure. Eur J Nucl Med 22:182-183, 1995
109. 99mTc-Sn-pyrophosphate compounds in the rat. I. In vivo studies. Nuklearmedizin 16:100-103, 1977
110. Levit N: Concentrated technetium and its effects on tagging efficiency. Monthly Scan Nov: 1, 1979
111. Sampson CB, Keegan J. Stability of WmTc-DTPA injection: Effect of delay after preparation, dilution, generator oxidant, air and oxygen. Nucl Med Commun 6:313-318, 1985
112. 99mTc-Sn-pyrophosphate compounds in the rat. II. In vitro studies. Nuklearmedizin 16:157-162, 1977
113. Inoue O, Ikeda I, Kurata K: Evaluation of two different HEDP content kits: stability study against dilution both in vivo and in vitro. Nuklearmedizin 21:121 -125, 1982
114. McCullough RW, Sheff MF, Tyson IB, et al: The nature of Tc-MDP complexes and their localization in vivo. Nucl Med Commun 6:548-549, 1985 (abstr)
115. 99mTc-sulfur colloid. J Nucl Med 10:319-320, 1969
116. 99mTc labeled, heat treated red blood cells. Radiology 136:501-503, 1980
117. 99mTc lung imaging kit. J Nucl Med Technol 5:28-31, 1977
118. 99mTc-MAA. Int J Nucl Med Biol 6:142-143, 1979
119. Davis MA. Jones AG, Trindade H: A rapid and accurate method for sizing radiocolloids. J Nucl Med 15:923-928, 1974
120. Heyman S, David MA, Shulkin PM, et al: Biologic evaluation of radiocolloids for bone marrow scintigraphy, in Sorenson JA: Radiopharmaceuticals II: Proceedings of the 2nd International Symposium on Radiopharmaceuticals: March 19-22, 1979, Seattle. New York, NY, Society of Nuclear Medicine, 1979, pp 593-601
121. Martindale AA, Papadimitrious JM, Turner JH: Technetium-99m antimony colloid for bone marrow imaging. J Nucl Med 21:1035-1041,1980
122. Kloiber R, Damtew B, Rosenthall L: A crossover study comparing the effect of particle size on the distribution of radiocolloid in patients. Clin Nucl Med 6:204-206, 1981
123. Adams FG, Horton PW, Selim SM: Clinical comparison of three liver scanning agents. Eur J Nucl Med 5:237-239,1980
124. Spencer RP: Role of radiolabeled erythrocyte in evaluation of splenic function. J Nucl Med 21:489-491, 1980
125. Campbell J, Bellen JC, Baker RJ: Technetium-9m calcium phytate-Optimization of calcium content for liver and spleen scintigraphy. J Nucl Med 22:157-160, 1981
126. Davis MA: Particulate radiopharmaceuticals for pulmonary studies, in Subramanian G, Rhodes BA, Cooper JF, et al (eds): Radiopharmaceuticals. New York, NY, Society of Nuclear Medicine, 1975, pp 267-281
127. Arroyo A, Jenkins T, Nelson J: Gallbladder (GB) visualization on routine lung perfusion. J Nucl Med Technol 22:122, 1994
128. Strout B, Hladik WB: Tc-MAA: focal hot spots. Monthly Scan Dec: 1-2, 1978
129. Vinberg GWM, Gerretsen M, Herscheid JDM, et al: Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 34:1953-1963, 1993
130. Heck LL, Duley JW: Statistical considerations in lung imaging with Tc albumin particles. Radiology 113: 675-679, 1974
131. Dworkin HJ, Gutkowski RF, Porter W, et al: Effect of particle number on lung perfusion images. J Nucl Med 18:260-262, 1977
132. Phipps P, Borharn P, Gonda I, et al: A rapid method for the evaluation of diagnostic radioaerosol delivery systems. Eur J Nucl Med 13:183-186, 1987
133. Schuster K, Peterson J, Sirr S, et al: Quality control in the production of radioaerosols. J Nucl Med Technol 15:97-98, 1987 (letter)
134. Miki M, Isawa T, Teshima T, et al: Difference in inhaled aerosol deposition patterns in the lungs due to three different sized aerosols. Nucl Med Commun 13:553-562, 1992
135. O'Doherty MJ, Miller RF: Aerosols for therapy and diagnosis. Eur J Nucl Med 20:1201-1213, 1993
136. O'Donoghue JP, Morrissey GJ, Biais M, et al: Pulse-microwaved technetium-99m labelled human erythrocytes for spleen scanning. Clin Nucl Med 19:933, 1994
137. Sirr SA, Juenemann PJ, Tom H, et al: Effect of ethanol on droplet size, efficiency of delivery, and clearance characteristics of technetium-99m DTPA aerosol. J Nucl Med 26:643-646, 1985
138. Sirr SA, Gramith F: Delivery efficiency of techne-tium-99m DTPA aerosol - Reply. J Nucl Med 27:1500,1986 (letter)
139. Porter WC, Juni JE, Dworkin HJ: Does ethanol improve aerosol ventilation scans? J Nucl Med 31:894,1990 (abstr)
140. Yano Y: Radionuclide generators: Current and future applications in nuclear medicine, in Subramanian G, Rhodes BA, Cooper JF, et al (eds): Radiopharmaceuticals. New York, NY, Society of Nuclear Medicine, 1975, pp 236-245
141. Coupai JJ, Shih WJ: Degraded bone image quality from Tc-99m generator eluate contaminants(s). J Nucl Med 27:1067,1986 (abstr)
142. Ponto JA: Effect of pertechnetate source and age on the radiochemical purity of technetium Tc 99m exametazime. Am J Hosp Pharm 45:2511-2513,1990
143. Sanderson JA, Kasina S, Rao TN, et al: Characterization and resolution of Mo-99/Tc-99m generated eluate contaminants interfering with -482 and NsS amide thiolate chelation. J Nucl Med 32:1102,1991 (abstr)
144. Van Duzee BF, Conway JJ, Cavanaugh DJ, et al: Radiopharmaceutical preparation conditions associated with abnormal soft-tissue localization of skeletal imaging agents. Pharm Pract 18:A-11,1983 (abstr)
145. Conway JJ, Weiss S, Van Duzee BF, et al: A comparative study of the effects of instant and generator produced technetium 99m on the nonosseous localization of skeletal imaging agents in children. J Nucl Med 23:P109, 1982 (abstr)
146. Webber MM, Cragin MD, Victery WK: Aluminum content in eluants from commercial technetium generators. J Nucl Med 12:700,1971 (letter)
147. Weinstein BM, Smoak W: The author's reply. J Nucl Med 11:767-768,1970 (letter)
148. Vinberg N, Kristensen K: Comparative evaluation of 99raTc-generators. Eur J Nucl Med 1:219-233,1976
149. Kelly WN, Ice RD: Pharmaceutical quality of technetium-99m sulfur colloid. Am J Hosp Pharm 30:817-820, 1973
150. Beightol TW, Cochrane J: Radiochemical analysis of commercial MDP bone kits. J Nucl Med Technol 11:173-176,1983
151. Zimmer AM, Pavel DG: Radiochemical evaluation and image correlation of stabilized and non-stabilized WmTc-Sn-diphosphonate kits. J Nucl Med Technol 5:54-55, 1977 (abstr)
152. Simon TR, Carrasquillo JA, Fejka R, et al: A clinical comparison of bone imaging agents. Nucl Med Biol 17:793795,1990
153. Simon TR, Carrasquillo JA, Fejka R, et al: A clinical evaluation of bone imaging kits. J Nucl Med 31:829, 1990 (abstr)
154. Vanbilloen HP, Verbeke KA, De Roo MJ, et al: Technetium-99m labelled human serum albumin for ventriculography: A comparative evaluation of six labeling kits. Eur J Nucl Med 20:465-472,1993
155. 99mTc macroaggregated albumin kits. J Nucl Med Technol 14:206-209, 1986
156. 99mTc-DTPA injection: Effect of delay after preparation, dilution, generator oxidant, air and oxygen. Nucl Med Commun 6:313-318, 1985
157. Russell CD, Bischoff PG, Rowell KL, et al: Quality control of Tc-DTPA for measurement of glomerular filtration. J Nucl Med 24:722-727,1983
158. 99mTc-DTPA prepared by three different methods. Radiology 98:674-676,1971
159. Pettit WA, DeLand FH, Pepper GH, et al: Characterization of tin-technetium colloid in technetium-labeled albumin preparations. J Nucl Med 19:387-392,1978
160. Nusynowitz ML, Straw JD, Benedetto AR, et al: Blood clearance rates of technetium-99m albumin preparations. J Nucl Med 19:1142-1145,1978
161. Kristensen K: Biodistribution in rats of 99m-Tclabelled human serum albumin. Nucl Med Commun 7:617-624,1986
162. Ford DR: Evaluation of commercially and electrolytically produced technetium Tc human serum albumin. Am J Hosp Pharm 35:1081-1083,1979
163. 99mTc(Sn)DTPA preparations used for the measurement of glomerular filtration rate. J Nucl Med 21:126-129,1980
164. 99mTc-DMS preparations obtained by labeling dimercaptosuccinate kits with different formulations. II. Comparison of chemical and biological characteristics of TcP-5 and MPI kits. Nuklearmedizin 20:46-49,1981
165. Fordham EW, Ali A, Turner DA, et al: Atlas of total body radionuclide imaging, vol 2, Philadelphia, PA, Harper & Row, 1982, pp 1587-1667
166. Louw WKA, Dormehl 1C, Hugo N, et al: Species and immunoglobulin preparation related effects on the biodistribution of technetium-99m-labelled immunoglobulin G in a baboon model. Eur J Nucl Med 20:96-100,1993
167. Hnatowich DJ, Mardirossian G, Rusckowski M, et al: Directly and indirectly technetium-99m-labeled antibodies-A comparison of in vitro and animal in vivo properties. J Nucl Med 34:109-119,1993
168. 2) méthylène diphosphonate complexes. J Nucl Med 26:524-530,1985
169. Seevers RH, Apodaca DM, Ryo UY, et al: Variations in quality of bone images obtained with four different preparations of MDP [abstractJ. J Nucl Med 26:P130, 1985
170. Pinkerton TC, Ferguson DL, Deutsch E, et al: In vivo distributions of some component fractions of Tc(NaBH,))-HEDP mixtures separated by anion exchange high performance liquid chromatography. Int J Appl Radiât Isot 33:907-915,1982
171. Verbruggen AM, de Roo MJK, Klopper JF: Technetium-99m diethylene triamine penta-acetic acid for intrathecal administration: Are we playing with fire? Eur J Nucl Med 21:261-263,1994
172. Keeling DH: Adverse reactions and untowards events associated with the use of radiopharmaceuticals, in Sampson CB (ed): Textbook of Radiopharmacy-Theory and Practice (ed 2). Langhorne, PA, Gordon and Breach, 1994, pp 285-298
173. 99mTc radiopharmaceuticals. Nucl Med Commun 4:368-371, 1983
174. Ponto JA, Preslar JS: Poor labeling of technetium99m RBCs in vivo associated with source of normal saline used for Sn-PYP reconstitution. J Nucl Med Technol 19:107-108, 1990 (letter)
175. Petry NA, Shaw SM, Keller WV, et al: Effect of rubber closures on the stability of stannous ion in reagent kits for radiopharmaceuticals. J Parent Drug Assoc 33:283286,1979
176. Millar AM: The absorption of 99mTc dimercaptosuccinic acid onto injection vials. Nucl Med Commun 5:195199, 1984
177. 99mTc generator technology. Int J Appl Radiât Isot 33:811-819,1982
178. Boyd RE: Technetium-99m generators-The available options. Int J Appl Radiât Isot 33:801-809, 1982
179. Nowotnik DP, Jurisson SS: Structure and stereochemistry in technetium coordination complexes, in Steigman J, Eckelman WX (eds): The Chemistry of Technetium in Medicine. Washington, DC, National Academy, 1992, pp 111-130
180. Sharp PF, Smith FW, Gemmell FG, et al: Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med 27:171-177, 1986
181. Ballinger JR, Reid RH, Gulenchyn KY: Technetium99m HM-PAO stereoisomers: Differences in interaction with glutathione. J Nucl Med 29:1998-2000, 1988
182. m d and / HMPAO. Nucl Med Commun 10:374, 1989 (abstr)
183. Walovitch RC, Makuch J, Knapik G, et al: Brain retention of Tc99m-ECD is related to in vivo metabolism. J Nucl Med 29:747, 1988 (abstr)
184. m-diastereomeric dimercaptosuccinic acid complexes: Comparison of their biodistribution. Nucl Med Commun 10:449-450, 1989
185. Morrissey GJ, Powe JE: Routine application of fractionated HMPAO stored at -70°C for WBC scintigraphy. J Nucl Med 35:151-155,1993
186. Reske SN, Buell U: Reduced technetium 99m labelled NCA-95/CEA-antibody uptake in liver to gentle antibody reconstitution. Eur J Nucl Med 17:38-41, 1990
187. Lin MS, Winchell S, Shipley BA: Use of Fe(II) or Sn(II) alone for technetium labeling of albumin. J Nucl Med 12:204-211,1971
188. Chi SL, Hoag SG, Yanchick VA: Electrolytic complexingof glucoheptonate and technetium-99m. J Nucl Med 19:520-524, 1978
189. 99mTc-D,L-HMPAO) using gentisic acid. Nucl Med Biol 16:675680, 1989
190. Bolstad DM, Valley TB, Wilson ME, et al: An improved method for reducing particle number in a technetium-99m macroaggregated albumin injection. J Nucl Med Technol 20:109, 1992 (abstr)
191. 99mTc-sulfur colloid prépara-tion containing disodium edetate. J Nucl Med 12:64-68, 1971
192. Feezer B: Clinical manifestation of a radiopharmaceutical formulation problem. Monthly Scan March:l-2, 1979
193. Taillefer R, Gagnon A, Lambert R, et al: Labeling procedure and in-vitro stability of Tc-99m methoxy isobutyl isonitrile (MIBI): Practical considerations. J Nucl Med 30:865,1989
194. Gagnon A, Taillefer R, Bavaria G, et al: Fast labeling of technetium-99m-sestamibi with microwave oven heating. J Nucl Med Technol 19:90-93,1991
195. Hung JC, Wilson ME, Brown ML, et al: Rapid preparation and quality control method for technetium-99m2-methoxy isobutyl isonitrile (technetium-99m-sestamibi). J Nucl Med 32:2162-2168,1991
196. Early PJ, Razzak MA, Sodée DB: Textbook of Nuclear Medicine Technology (ed 3). St Louis, MO, Mosby, 1979, pp 363-370
197. 99mTc-labeled, heat-treated red blood cells. Radiology 138:207-209,1981
198. Som P, Ansari AN, Oster ZH, et al: Effects of heating on the size-distribution and differential uptake of ''Tc-red blood cells (RBC) by spleen and liver. J Nucl Med 21:P44,1980(abstr)
199. Larson SM, Nelp WB: Radiopharmacology of a simplified technetium-99m colloid preparation for photoscanning. J Nucl Med 7:817-826, 1966
200. Frier M, Griffiths P, Ramsey A: The physical and chemical characteristics of sulphur colloids. Eur J Nucl Med 6:255-260, 1981
201. Morrissey GJ, Powe JE: Microwave preparation of technetium-99m sulfur colloid. J Nucl Med Technol 20:159162, 1992
202. Anderson R, Kernel A, Sajdak R, et al: Ultrasafe microwave preparation of Tc-99m cold kits. J Nucl Med Technol 22:114,1994
203. Hollar BS, Hung JC, Hauser MF: Evaluation of the microwave heating technique as an alternative method for preparing technetium-99m-sulfur colloid. J Nucl Med Technol 23:77-81,1995
204. Valk PE, Guille J: Measurement of splenic function with heat-damaged RBCs: Effect of heating conditions: concise communication. J Nucl Med 25:965-968,1984
205. Armas RR, Thakur ML, Gottschalk A: A simplified method of selective spleen scintigraphy with Tc-99mlabeled erythrocytes: Clinical applications. J Nucl Med 21:413-416, 1980
206. Som P, Oster ZH: Spleen scanning with Tclabeled red blood cells (RBC). J Nucl Med 21:1000, 1980 (letter)
207. 99mTc-labeled red blood cells (RBC). Reply. J Nucl Med 21:1000-1001, 1980 (letter)
208. Hung JC, Wilson ME, Brown ML: Rapid preparation and quality control of technetium-99m MAG3. J Nucl Med Technol 19:176-179, 1991
209. Wilson ME, Hung JC, Gibbons RJ: An alternative method for rapid preparation of 99mTc-sestamibi. Nucl Med Commun 14:544-549, 1993
210. Parrott SJ, Carroll TR: Determination of the chemistry of a Cardiolitekit. J Nucl Med 35:138P, 1994
211. Wilson ME, Hung JC: Microwave preparation of and one-strip paper chromatography for technetium Tc 99m teboroxime. Am J Hosp Pharm 50:2376-2379,1993
212. 22:124,1994
213. -iomazenil. J Nucl Med36:1151P-152P, 1995
214. Evdokimoff VN: Hot lab radiopharmaceutical accident: Potential airborne release. Health Physics 39:573-574, 1980
215. Hung JC, Gibbons RJ: Breakage of technetium-99msestamibi vial with the use of a microwave oven. J Nucl Med 33:176-178,1992 (letter)
216. Steigman J, Eckelman WC: The Chemistry of Technetium in Medicine. Washington, DC, National Academy, 1992
217. 99mTc: A new approach to blood pool localization. J Nucl Med 18:305-308,1977
218. Staub RF, Srivastava SC, Meinken GE, et al: Transport, binding, and uptake kinetics of tin and technetium in the in-vitro Tc-99m labeling of red blood cells. J Nucl Med 26:P130-P-131,1985
219. Froelich JW, Callahan RJ, Leppo J, et al: Time course of in vivo labelling on red blood cells. J Nucl Med 21:P44, 1980(abstr)
220. 99mTc. Am J Hosp Pharm 38:19391941, 1981
221. Blauenstein P, Iftimia M, Argentini M, et al: The Tc-DTPA-complex: New aspects on an old but not yet solved problem. Eur J Nucl Med 8:A46, 1983 (abstr)
222. Groth S, Mortensen J, Funch-Rosenberg H, et al: Ultrasound nebulization does not cause chemical breakdown of 99m-Tc-DTPA. J Nucl Med 29:905,1988 (abstr)
223. 99mTc to hemoglobin (Hgb) in the intact cell and Hgb solution. J Nucl Med 22:P70, 1981 (abstr)
224. 99mTc. J Nucl Med 23:315-318,1982
225. Callahan RJ, Rabito CA: Radiolabeling of erythrocytes with technetium-99m: Role of band-3 protein in the transport of pertechnetate across the cell membrane. J Nucl Med 31:2004-2010,1990
226. Karesh SM: Technetium-99m-exametazime: Pitfalls in preparation and quality control. J Nucl Med Technol 17:215-218,1989
227. Henkin RE, Woodruff A, Chang W, et al: The effect of radiopharmaceutical incubation time on bone scan quality. Radiology 135:463-466, 1980
228. 99mTc MDP. J Nucl Med 23:214-217, 1982
229. Darte L: A comparative investigation of the gel chromatography column scanning method for quality control of 99mTc-methylenediphosphonate. Nuklearmedizin 20: 51-63, 1981
230. Wilson MA, Pollack MJ: Gastric visualization and image quality in radionuclide bone scanning. J Nucl Med 22:518-521,1981
231. Van Duzee BF, DePrato DW, Cavanaugh DJ, et al: A multi-site clinical study of factors including soft-tissue localization of skeletal imaging agents in children. J Nucl Med 23:P99,1982 (abstr)
232. Babich JW, Graham W, Barrow S, et al: Tc-99mlabeled chemotactic peptides: influence of co-ligand on speciation and infection imaging properties. J Nucl Med 36:206P, 1995
233. Roddie ME, Peters AM, Danpure HJ, et al: Inflammation: Imaging with Tc-99m HMPAO-labeled leukocytes. Radiology 166:767-772, 1988
234. Puncher MRB, Blower PJ: Autoradiography and density gradient separation of technetium-99m-exametazime (HMPAO) labelled leucocytes reveals selectivity for eosinophils. Eur J Nucl Med 21:1175-1182,1994
235. Sullivan RM: Professional communication letter. North Billerica, MA, DuPont, 1988
236. Hung JC, Wilson ME: Optimal volume of anticoagulant citrate dextrose solution in the preparation of technetium Tc 99m-labeled red blood cells. Am J Hosp Pharm 51:2699-2701,1994
237. Srivastava SC, Sträub RF: Blood cell labeling with Tc: Progress and perspectives. Semin Nucl Med 20:41-51. 1990
238. Bernardo-Filho M, Gutfilen B, De Souza Maciel O: Effect of different anticoagulants on the labeling of red blood cells and plasma proteins with wTcm. Nucl Med Commun 15:730-734, 1994
239. Chowdhury S, Dewanjee MK, Hung JC, et al: Affect of anticoagulant, heparin vs ACD on the binding of Tc-99m to hemoglobin and red cell membrane-proteins. J Nucl Med Technol 19:118, 1991 (abstr)
240. Bonacorrsi J, Russell JK, Rodriguez A, et al: Heparin vs ACD anticoagulant effect on Tc99m RBC in vitro labeling. A quantitative analysis. J Nucl Med Technol 20:107,1992 (abstr)
241. Mayer K, Dwyer A, Laughlin JS: Spleen scanning using ACD-damaged red cells tagged with 51Cr. J Nucl Med 11:455-458, 1971
242. McAfee JG, Gagne GM, Subramanian G, et al: Distribution of leukocytes labeled with In-Ill oxine in dogs with acute inflammatory lesions. J Nucl Med 21:1059-1068, 1980
243. Kowalsky RJ, Chilton HM: Re: Stability of stannous ion in stannous pyrophosphate kits. J Nucl Med 24:10801081, 1983 (letter)
244. Thornton AK, Molinski VJ, Spencer JT: Radiolytic production of peroxides in technetium-99m solutions. J Nucl Med 20:653, 1979 (abstr)
245. Waldman DL, Weber DA, Oberdorster G, et al: Chemical breakdown of radioaerosols during nebulization. J Nucl Med 26:P131, 1985 (abstr)
246. Waldman DL, Weber DA, Oberdorster G, et al: Chemical breakdown of technetium-99m DTPA during nebulization. J Nucl Med 28:378-382, 1987
247. Huchon GJ, Montgomery AB, Lipavsky A, et al: Respiratory clearance of aerosolized radioactive solutes of varying molecular weight. J Nucl Med 28:894-902,1987
248. Yu TW, Lin HM, Liu RS, et al: Evaluation of Tc-99m HMPAO radiochemical purity prepared by ultrasound and jet nebulizer. J Nucl Med 35:244P, 1994
249. Kelbaek H, Bulow K, Aldershvile J, et al: A new 99mTc-red blood cell labeling procedure for cardiac blood pool imaging: Clinical results. Eur J Nucl Med 15:333-335, 1989
250. Patrick St, Glowniak JV, Turner FE, et al: Comparison of in vitro RBC labeling with UltraTag RBC kit versus in vivo labeling. J Nucl Med 32:242-244,1991
251. Ryo UY, Mohammadzadeh AA, Siddiqui A, et al: Evaluation of labeling procedures and in vivo stability of 99mTc-red blood cells. J Nucl Med 17:133-136,1976
252. Kobayashi H, Suzuki KH, Sakahara H, et al: Oxygen bubbling can improve the labelling of pentavalent technetium-99m dimercaptosuccinic acid. Eur J Nucl Med 22:559562,1995
253. Hotte CE, Ice RD: The in vitro stability of [B1I]oiodohippurate. J Nucl Med 20:441-447,1979
254. Der M, Ballinger JR, Bowen BM: Decomposition of 99mTc pyrophosphate by peroxides in pertechnetate used in preparation. J Nucl Med 22:645-646,1981
255. Zimmer AM, Spies SM: Quality control of unidose dispensed radiopharmaceuticals: Correlation to vial preparations. Pharm Pract 17:A-17,1982 (abstr)
256. Millar AM, Wathen CG, Muir AL: Failure in labelling of red blood cells with 99mTc: interaction between intravenous cannulae and stannous pyrophosphate. Eur J Nucl Med 8:502-504,1983
257. Dhawan V, Yeh DJ: Labeling efficiency and stomach concentration in méthylène diphosphonate bone imaging. J Nucl Med 20:791-793,1979
258. Coupai JJ, Kim EE, DeLand FH: Effects of dissolved oxygen on 99mTc méthylène diphosphonate. J Nucl Med 22:153-156,1981
259. Tofe AJ, Bevan JA, Fawzi MD, et al: Gentisic acid: A new stabilizer for low tin skeletal imaging agents. J Nucl Med 21:366-370,1980
260. Hesslewood SR: Quality control procedures for 99mTc complexes. Nuklearmedizin 20:3-6,1981
261. Jovanovic V, Konstantinovska D, Memedovic T: Determination of radiochemical purity and stability of 99mTc-diethyl HIDA. Eur J Nucl Med 6:375-378,1981
262. Majewski W, Zimmer AM, Spies SM: Radiochemical evaluation of commercial hepatobiliary IDA radiopharmaceuticals [abstractJ. J Nucl Med Technol 9:116,1981
263. Weisner PS, Bower GR, Dollimore LA, et al: A method for stabilizing technetium-99m exametazime prepared from a commercial kit. Eur J Nucl Med 20:661-666, 1993
264. 99mTc stannous DTPA kits using a new chromatography technique. J Nucl Med Technol 3:208209,1975
265. Zbrzeznj DJ, Khan RAA: Factors affecting the labeling efficiency and stability of technetium-99m-labeled glucoheptonate. Am J Hosp Pharm 38:1499-1502,1981
266. Collins HR, Kavula M, Solomon AC: Stability of unit-dose technetium-99m radiopharmaceuticals: radiochemical purity of multidose syringe. Pharm Pract 18:A-12, 1983
267. 99mTc Sn glucoheptonate: A professional dialogue. Monthly Scan Sept:l, 1978
268. Taylor A, Lallone RL, Hagan PL: Optimal handling of dimercaptosuccinic acid for quantitative renal scanning. J Nucl Med 21:1190-1193,1980
269. 99mTc DMSA. View Box 2:1-2,1983
270. Hayes AC: Effects of multiple factors on the stability of new technetium-99m labeled radiopharmaceuticals: MAG3, Cardiolite, and CardioTec. J Nucl Med Technol 20:84-87,1992
271. Krejcarek GE, Heerwald PE, Tucker KL, et al: The chemistry of stannous dimercaptosuccinic acid chelates. J Labelled Comp Radiopharm 13:157,1977 (abstr)
272. Ballinger J, Der M, Bowen B: Stabilization of 99mTc-pyrophosphate injection with gentisic acid. Eur J Nucl Med 6:153-154,1981
273. Cheng KT, Lape L, Sheppard MS, et al: The use of ascorbic acid to stabilize Tc-99m HDP with high radioactivity. Presented at the APhA Annual Meeting, Orlando, FL, March 18-21,1995
274. Glenn HJ, Kidwell RE: Radioactive pharmaceuticals and the concept of stability, in Andrews GA, Kniseley RM, Wagner HN (eds): Radioactive Pharmaceuticals. Oak Ridge, TN, US Atomic Energy Commission, 1966, pp 165-175
275. Bell EG, McAfee JG, Subramanian G: Radiopharmaceuticals in pediatrics, in James AE, Wagner HN, Cooke RE (eds): Pédiatrie Nuclear Medicine. Philadelphia, PA, Saunders, 1974, pp 84-94
276. Dworkin HJ, Nelis A, Dowse L: Rectilinear liver scanning with technetium-99m sulfide colloid. Am J Roentgenol Rad Ther 101:557-560,1967
277. Craggin MD, Webber MM, Victery WK: Effect of aluminum concentration in technetium eluent on particle size. J Nucl Med 12:476,1971 (abstr)
278. Rhodes BA, Croft BY: Basics of Radiopharmacy. St Louis, MO, Mosby, 1978
279. United States Pharmacopeial Convention: Sodium pertechnetate Tc 99m injection, in The United States Pharmacopeia XXII. Rockville, MD, United States Pharmacopeial Convention, 1994, pp 1486-1487
280. Zabel PL, Chamberlain MJ, Stephenson Ja, et al: Aluminum from needles resulting in instability and altered biodistribution of radiopharmaceuticals. J Nucl Med 27: 942,1986 (abstr)
281. Adams EH, Chandler RP, Farkas RJ: Sulfur colloid flocculation due to acid-leached aluminum. J Nucl Med 12:707-708,1972
282. 99mTc-sulfur colloid containing aluminum ion. J Nucl Med 13:386-387,1972
283. 99mTc sulfur colloid preparations with different buffers. J Nucl Med Technol 12:16-18,1984
284. 3+ in plasma. J Nucl Med 15:1220-1222,1974
285. Miller W: Technetium-99m biorouting, in Early PJ, Razzak MA, Sodée DB (eds): Textbook of Nuclear Medicine Technology (ed 3). St Louis, MO. Mosby, 1979, pp 544-570
286. Chia HL, De Schrijver M: Modified in vivo behavior of -99m-Tc-labeled liver-spleen preparations due to '''Mo/ g9mTc-generator eluate impurities. Eur J Nucl Med 8:450453,1983
287. 99mTc-diphosphonate. Radiology 119:485-486,1976
288. 99mTc-EHDP. Int J Nucl Med Biol 3:37-40,1976
289. Jaresko GS, Zimmer AM, Pavel DG, et al: Effect of circulating aluminum on the biodistribution of Tc-99m-Sndiphosphonate in rats. J Nucl Med Technol 8:160-161, 1980
290. Specht HD, Belsey R, Hanada J: Aluminemic disturbance of technetium-99m DTPA renal function measurement. J Nucl Med 28:383-386. 1987
291. 99mTc] pertechnetate in iatrogenic hyperaluminemia. J Nucl Med 19:381-383, 1978
292. Shukla SK, Manni GB, Cipriani C: Effect of aluminum impurities in the generator-produced pertechnetate99m ion on thyroid scintigrams. Eur J Nucl Med 2:137-141, 1977
293. Lin MS, MacGregor RD, Yano Y: Ionic aluminum (III) in generator eluate as an erythrocyte-agglutinating agent. J Nucl Med 12:297-299, 1971
294. 99mTc-pyrophosphate (PYP) in bone imaging. Med Imaging 2:39, 1977 (abstr)
295. Russell CD, Cash AG: Oxidation state of technetium in bone scanning agents, in Sorenson JA: Radiopharmaceuticals II: Proceedings of the 2nd International Symposium on Radiopharmaceuticals: March 19-22, 1979, Seattle. New York, NY, Society of Nuclear Medicine, 1979, pp 627-636
296. Libson K, Deutsch E. Heineman WR, et al: Preparative control, HPLC analysis, and in vivo evaluation of components of a technetium-MDP radiopharmaceutical mixture. J Nucl Med 24:P23, 1983 (abstr)
297. Tanabe S, Zodda JP, Deutsch E, et al: Effect of pH on the formation of Tc(NaBH4)-MDP radiopharmaceutical analogues. Int J Appl Radiât Isot 34:1577-1584, 1983
298. Krejcarek GE. Wicks JH, Heerwald PE, et al: The structure of stannous dimercaptosuccinic acid chelates. J Nucl Med 17:565, 1976 (abstr)
299. 99mTc-DMSA. J Nucl Med 24:P126-127, 1983 (abstr)
300. 99mTc(V)-dimercaptosuccinic acid preparations. Appl Radiât Isot 38:13-18, 1987
301. Hirano T, Tomiyoshi K, Zhang YJ, et al: Preparation and clinical evaluation of technetium-99m dimercaptosuccinic acid for tumor scintigraphy. Eur J Nucl Med 21:82-85. 1994
302. 99mTc iminodiacetate hepatobiliary agents and a question of multiple peaks. J Nucl Med 21:1180-1184, 1980
303. Harper PV, Lathrop KA, Gottschalk A: Pharmacodynamics of some technetium-99m preparations, in Andrews GA, Kniseley RM, Wagner HN (eds): Radioactive Pharmaceuticals. Oak Ridge. TN, US Atomic Energy Commission, 1966, pp 67-91
304. Scheffel U, Tsan MF, Mclntyre PA: Labeling of human platelets with [ ' ' 'In]8-hydroxyquinoline. J Nucl Med 20:524-531.1979
305. Bauman JM, Landry AJ: Practical platelet labeling with indium-111-oxine. J Nucl Med Technol 14:15-17, 1986
306. Peters AM: Review of platelet labelling and kinetics. Nucl Med Commun 9:803-809, 1988
307. Study KT, Schultz HW. Laven DL: The effect of bacteriostatic saline on -4Tc-labeled radiopharmaceuticals. J Nucl Med Technol 9:115-116, 1981
308. Charlton JC: Problems characteristic of radioactive pharmaceuticals, in Andrews GA, Kniseley RM, Wagner HN (eds): Radioactive Pharmaceuticals. Oak Ridge, TN, US Atomic Energy Commission, 1966, pp 33-50
309. Fisher SM, Brown RG, Greyson ND: Unbinding of
310. Peterson EM, Ryan JW, Martin WB: Gastric activity on Tc-99m oxidronate bone scans can be caused by isopropyl alcohol. J Nucl Med 27:1090, 1986 (abstr)
311. Murray T. Hilditch TE, Whateley TL, et al: Formation of labelled colloid in 9Tcm-DMSA due to the presence of bactericidal fluid. Nucl Med Commun 7:505-510, 1986
312. Sampson CB: Altered biodistribution of radiopharmaceuticals as a result of pharmacological or chemical interaction, in Theobald AE (ed): Radiopharmacy and Radiopharmaceuticals. London, England, Taylor and Francis, 1985, pp 189-205
313. 99mTc-sulfur colloid. Semin Nucl Med 10:106-107, 1980
314. Pedersen B, Kristensen K: Evaluation of methods for sizing of colloidal radiopharmaceuticals. Eur J Nucl Med 6:521-526, 1981
315. 99mTc-Sn-colloid incubation time on in vivo distribution. Eur J Nucl Med 8:335-337, 1983
316. m1 labelled colloids to glass vials. Nucl Med Commun 11:375-381. 1990
317. m-tin colloid preparation. Nucl Med Commun 7:845-850, 1986
318. Thakur ML. Coleman RE, Welch MJ: Indium-111labeled leukocytes for the localization of abscesses: Preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med 89:217-228, 1977
319. Karesh SM, Henkin RE: Preparation of ' ' 'In leukocytes after hemolytic removal of erythrocytes. Nucl Med Biol 14:79-80, 1987
320. Segal AW, Deteix P. Garcia R, et al: Indium-111 labeling of leukocytes: A detrimental effect on neutrophil and lymphocyte function and an improved method of cell labeling. J Nucl Med 19:1238-1244. 1978
321. Thakur ML. Lavender JP. Arnot RN. et al: Indium-111-labeled autologous leukocytes in man. J Nucl Med 18:1012-1019,1977
322. Loken MK, Clay ME, Carpenter RT, et al: Clinical use of Indium-111 labeled blood products. Clin Nucl Med 10:902-911,1985
323. Chowdhury S, Thorson L, Jenkins D, et al: Separation and labeling of human leukocytes by two methods for the detection of infectious, inflammatory disease and graft infection. J Nucl Med Technol 19:118,1991 (abstr)
324. Baker WJ, Datz FL: Preparation and clinical utility of In-Ill labeled leukocytes. J Nucl Med Technol 12:131136,1984
325. Thakur ML, Walsh L, Malech JL, et al: Indium-111labeled human platelets: improved method, efficacy, and evaluation. J Nucl Med 22:381-385,1981
326. Isaka Y, Kimura K, Matsumoto M, et al: Functional alterations of human platelets following indium-Ill labelling using different incubation media and labeling agents. Eur J Nucl Med 18:326-331,1991
327. Goodwin DA, Bushberg JT, Doherty PW, et al: Indium-lll-labeled autologous platelets for location of vascular thrombi in humans. J Nucl Med 19:626-634, 1978
328. Mortelmans L, Verbruggen A, de Roo M, et al: Evaluation of three methods of platelet labeling. Nucl Med Commun 7:519-529,1986
329. Chowdhury S, Pineda AA, Zylstra V, et al: Saline washing affects in-vivo recovery and platelet function. J Nucl Med Technol 17:113,1989 (abstr)
330. Coupai JJ, Hughes J, Ryo UY, et al: Sedimentation characteristics of several Tc-99m aggregated albumin radiopharmaceuticals. J Nucl Med 29:904,1988 (abstr)
331. 99mcm-labelled macroaggregates or microspheres of albumin-Any basis? Nucl Med Commun 15:188-191,1994
332. 99mcm-MAA onto vials and syringes. Nucl Med Commun 6:550, 1985 (abstr)
333. 99mc-sulfur colloid. J Nucl Med 10:395-396,1969
334. Porter WC, Dworkin HJ, Gutkowski RF: Vial retention of technetium-99m sulfur colloid in commercial kits. Am J Hosp Pharm 32:1141-1143,1975
335. Millar AM: The economical use of wTcm-hexamibi kits. Nucl Med Commun 10:247,1989 (abstr)
336. Hartman NG: Out of sight, out of mind! J Nucl Med 35:1569-1570,1994
337. Pendleton D, Threadgill T: Caution urged in using microwaved technetium-99m sestamibi. J Nucl Med Technol 21:46,1993
338. Hung JC: Photochemical considerations of lightsensitive cold kits and radiopharmaceuticals. J Nucl Med Technol 21:90-91,1993
339. Chilton HM: Light-sensitive cold kits and radiopharmaceuticals. Hepatolite. J Nucl Med Technol 22:261,1994
340. Loberg M: The study of organ function using radiolabeled drugs. Presented at the 128th Annual Meeting of the American Pharmaceutical Association, St Louis, MO, March 30,1981
341. 99mcJTc-HEDP preparations that can be expected to give a better lesion-to-normal-bone uptake ratio when used as bone scanning agent. Nucl Med Biol 20:23-29,1993
342. Goldenberg DM, DeLand F, Kim E, et al: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384-1388,1978
343. Goldenberg DM: Tumor imaging with monoclonal antibodies. J Nucl Med 24:360-362,1983
344. Katzenellenbogen JA, Carlson KE, Heiman DF, et al: Receptor-binding radiopharmaceuticals for imaging breast tumors: estrogen-receptor interactions and selectivity of tissue uptake of halogenated estrogen analogs. J Nucl Med 21:550-558,1980
345. Feenstra A, Vaalburg W, Noten GMJ, et al: Estrogen receptor binding radiopharmaceuticals. II. Tissue distribution of 17 a-methylestradiol in normal and tumor-bearing rats. J Nucl Med 24:522-528,1983
346. Larson SM, Brown JP, Wright PW, et al: Imaging of melanoma with 1-131 labeled monoclonal antibodies. J Nucl Med 24:123-129,1983
347. Shearer DR, Pezzullo JC, Moore MM, et al: Radiation dose from radiopharmaceuticals contaminated with molybdenum-99. J Nucl Med 29:695-700,1988
348. Kowalsky RJ, Preslar J: Report of a positive Mo-99 breakthrough test. J Nucl Med Technol 7:108, 1979 (letter)
349. 99mTc. J Nucl Med Technol 9:40-41,1981
350. Smart RC, Lyons NR, McLean RG: Delivery efficiency of technetium-99m DTPA aerosol. J Nucl Med 27:1500,1986 (abstr)
351. Christian PE, Datz FL, Sorenson JA, et al: Technical factors in gastric emptying studies. J Nucl Med 24:264267,1983
352. Malmud LS, Fisher RS, Knight LE, et al: Scintigraphic evaluation of gastric emptying. Semin Nucl Med 12:116-125,1982
353. Leb G, Lipp RW: Criteria for labelled meals for gastric emptying studies in nuclear medicine. Eur J Nucl Med 20:185-186,1993
354. Dansereau RN, Line BR: Effect of number of oral Tc-99m labeled hard gelatin capsules on gastric residence time and capsule disintegration time. J Nucl Med 36:64P, 1995
355. Grayson RR: Factors which influence the radioactive iodine thyroidal uptake test. Am J Med 28:397-415, 1960
356. Sternthal E, Lipworth L, Stanley B, et al: Suppression of thyroid radioiodine uptake by various doses of stable iodine. N Engl J Med 303:1083-1088,1980
357. Schomacker K, Wellner U, Gabruk-Szostak B, et al: Properties of 1-131 therapy capsules effect the radioiodinebiokinetics. J Nucl Med 36:79P, 1995
358. McDonald M: Personal communication. St Louis, MO, Mallinckrodt Medical Inc, 1994
359. Gobern J, Lyman F: Professional communication letter. Princeton, NJ, Cytogen, 1994
360. Oswald WM, Hung JC, Gross GP: A study to measure the volatility of liquid 1-131 for clinical applications. J Nucl Med Technol 22:123, 1994
361. Saha GB: Fundamentals of Nuclear Pharmacy (ed 3). New York, NY, Springer-Verlag, 1992
362. Baker GA, Lum DJ, Smith EM, et al: Significance of radiocontaminants in 123I for dosimetry and scintillation camera imaging. J Nucl Med 17:740-743,1976
363. Suzuki A, Suzuki MN, Weis AM: Analysis of a radioisotope calibrator. J Nucl Med Technol 4:193-198, 1976
364. Johnson AS, Baker SI, Arnold JE, et al: Radionuclide impurities in commercial 123I and their influence on the dose calibrator assay of 123I. J Nucl Med 16:540, 1975 (abstr)
365. Hughes JA, Williams CC, Thomas SR, et al: Potential errors caused by variable radionuclidic purity of I23I. J Nucl Med Technol 7:167-170,1979
366. Chervu S, Chervu LR, Goodwin PN, et al: Thyroid uptake measurements with 123I: Problems and pitfalls. J Nucl Med 23:667-670,1982
367. Johnson AS, Colombetti LG, Baker SI, et al: Dose calibrator readings due to radionuclidic impurities found in radiopharmaceuticals. Nuklearmedizin 19:1-6, 1979
368. Grossman LW, Lukes SJ, Kruger JB, et al: The influence of measurement technique and 124I contamination on 123I thyroid uptake determinations. J Nucl Med 24:P104, 1983 (abstr)
369. Polak JF, English RJ, Holman BL: Performance of collimators used for tomographic imaging of I23I contaminated with 124I. J Nucl Med 24:1065-1069,1983
370. Madsen MT, Patel J, Thakur ML, et al: Collimator selection and 124I contamination determination for 123I imaging studies. J Nucl Med 25:P106,1984 (abstr)
371. Kasulis PW, Hill TC, Lee RG, et al: Comparison of gamma camera response to 123I(p,5n) and 123I(p,2n). J Nucl Med Technol 12:90-91,1984 (abstr)
372. Groch MW, Lewis GK: Thallium-201: scintillation camera imaging considerations. J Nucl Med 17:142-145, 1976
373. Hines HH, Lagunassolar MC: The effect of different levels of 202T1 and 200T1 radiocontamination on 201TI imaging. J Nucl Med 21:P51, 1980 (abstr)
374. Ricciardone M, Frey GD, Levine E: Imaging effects of the radiocontaminant 20(IT1 from 4-day precalibrated lots of a commercially produced 201T1. Presented at the Twentyfourth Annual Meeting of the Southeastern Chapter of the Society of Nuclear Medicine, Orlando, FL, 1983
375. Scheffel U, Tsan MF, Mclntyre PA: Labeling of human platelets with [lnln] 8-hydroxyquinoline. J Nucl Med 20:524-531, 1979
376. Wistrow BW, Grossman ZD, McAfee JG, et al: Labeling of platelets with oxine complexes of Tc-99m and In-Ill. Part 1. In vitro studies and survival in the rabbit. J Nucl Med 19:483-487, 1978
377. Thakur ML, Welch MJ, Joist JH, et al: Indium-111 labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res 9:345-347,1976
378. Schmelter R: Professional communication letter. Princeton, NJ, Cytogen, 1993
379. Seevers RJ, Patel B, Blend MJ: The importance of careful filtration technique in obtaining high recovery yields of indium-Ill OncoScint CR/OV. J Nucl Med Technol 22:70-73, 1994
380. Forstrom L: Clinical experience using In-111-leukocytes in 1001 cases. Presented at the Fourth Annual Midwestern Cell Labeling Conference, Iowa City, I A, 1983
381. Yu WKS, Peck GE, Shaw SM: A comparison of the dissolution profiles for several commercially available therapeutic [131I] sodium iodide capsules. Nucl Med Biol 17:465467,1990
382. Yu WKS, Shaw SM, Peck GE: Determination of dissolution profiles for several commercially available therapeutic [131I] sodium iodide capsules. Nucl Med Biol 17:465467, 1990
383. Clanton JA, Chilton HM, Laven DL, et al: Volatility of 1-131 therapy solutions for oral administration: A multicenter study. Princeton, NJ, Squibb, 1989
384. Clanton JA, Seibert J, Sneed D: Volatility of therapeutic 1-131 sodium iodide solutions for oral administration. J Nucl Med 27:1092,1986 (abstr)
385. Hammermaier A, Reich E, Bogl W: Radiochemical purity and in vitro stability of commercial hippurans. J Nucl Med 27:850-854, 1986
386. Kosterink JGW, Boorsma JH, Franssen JF, et al: Simple purification and quality control of radioiodinated hippuran for the estimation of effective renal plasma flow. Eur J Nucl Med 22:587,1995
387. Kengen RAM, Meijer S, van Zanten AK, et al: Iodine-131 hippuran for the estimation of renal plasma flow: requirements for radiochemical purity. Eur J Nucl Med 22:678-681, 1995
388. Waxman AD, Siemsen JK, Lee GC, et al: Reliability of gallium brain scanning in the detection and differentiation of central nervous system lesions. Radiology 116:675678,1975
389. Spicer JA, Hannesen R, Baranczuk RJ: A comparison of radiochemical purity and reaction yields of iodine 123 sodium iodide solutions. J Nucl Med 31:947,1990 (abstr)
390. Miller K: Tumor imaging with radiolabeled peptides. Presented at APhA Annual Meeting, Seattle, WA, March 19,1994
391. Technical Bulletin: Effects of Monoject syringes on Octreoscanlabeling. St Louis, MO, Mallinckrodt Medical, Inc, 1994
392. Borys N: Professional communication letter; personal communication. Arlington Heights, IL, Medi-Physics, Inc, 1993
393. Weiblen BJ, Forstrom L, McCullough J: Studies of the kinetics of indium-111-labeled granulocytes. J Lab Clin Med 94:246-255,1979
394. Ponto JA, Seabold JE: Time course of indium-111 oxine labeling of human leukocytes. Nucl Med Commun 5:769-773,1984
395. McAfee JG, Thakur ML: Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents. J Nucl Med 17:480-487, 1976
396. Paavola PC, Carrimon FL, Thorson LM, et al: Optimal storage temperatures and times for indium-111-oxine labeled leukocytes. J Nucl Med Technol 36:126, 1995
397. Thorson LM, Turkalj A, Hung JC: In vitro viability analysis of timed hypotonie lysis on ficoll-hypaque separated granulocytes. J Nucl Med 36:206P-207P, 1995
398. Hill-Zobel RL: Cannon S. McCandless B, et al: Effects of chelates and incubation media on platelet labeling with indium-111. J Nucl Med 28:223-228, 1987
399. Steffel FG, Rao S: Rapid and simple methods for labeling white blood cells and platelets with indium-111-oxine. J Nucl Med Technol 15:61-65, 1987
400. Dewanjee MK, Chowdhury S, Brown ML, et al: Distribution of In-Ill in granulocyte and other cellular elements of blood (CEB) in human In-111-labeled mixed white cell (MWC) and platelet preparations. J Nucl Med 25:P98, 1984 (abstr)
401. Goodgold HM, Gentilcore RC, Hendershott L, et al: Significance of diffuse cardiac activity on In-111 labeled leucocyte scans. Eur J Nucl Med 12:271-273, 1986
402. Gilbert BR, Cerqueira MD, Via HW, et al: Indium-111 labeled leukocyte uptake: False-positive results in noninfectedpseudoaneurysms. Radiology 158:761-763,1986
403. Brown BM, Cheng KT, Gordon L, et al: The sedimentation method for leukocyte labeling. J Nucl Med Technol 20:108, 1992 (abstr)
404. 111In-mercaptopyridine-N-oxide in plasma containing acid-citrate-dextrose. Br J Radiol 59:907-910, 1986
405. MacGregor RR, Schlyer DJ, Fowler JS, et al: Fluorine-18-N-methylspiroperidol:radiolytic decomposition as a consequence of high specific activity and high dose levels. J Nucl Med 28:60-67, 1987
406. Frincke JM, Halpern SE, Hagan PL, et al: The effect of radioautolysis onY antibody (Ab) preparations. J Nucl Med 28:711, 1987 (abstr)
407. Wafelman AR, Suchi R, Hoefnagel ÇA, et al: Radiochemical purity of iodine-131 labelled metaiodobenzylguanidine infusion fluids: A report from clinical practice. Eur J Nucl Med 20:614-616, 1993
408. Wafelman AR, Hoefnagel CA, Beijnen JH: Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use. Nucl Med Commun 14:819-822, 1993
409. McAfee JG, Grossman ZD, Gagne G, et al: Comparison of renal extraction efficiencies for radioactive agents in the normal dog. J Nucl Med 22:333-338, 1981
410. Visser GWM, Gerretsen M, Herscheid JDM, et al: Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 34:1953-1963, 1993
411. Chakrabarti MC, Le N, Paik CH, et al: Preservation of antibody immunoreactivity by various radioprotectants. J Nucl Med 36:79P, 1995
412. Wahl RL, Wissing J, del Rosario R, et al: Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 31:84-89, 1990
413. Hunter WW, Kulkarni MV, Price R: Thallous vs thallic Tl-201: Factors influencing biodistribution and myocardial turnover. J Nucl Med 22:P82, 1981 (abstr)
414. Pathy MS, Kirkman S, Molloy MJ: An evaluation of simultaneously administered free and intrinsic factor bound radioactive cyanocobalamin in the diagnosis of pernicious anemia in the elderly. J Clin Pathol 32:244-250, 1979
415. Choy YC, Kim EE, Domstad PA, etal: Reliability of dual isotope Schilling test for the diagnosis of pernicious anemia or malabsorption syndrome. J Nucl Med 21:P26, 1980(abstr)
416. 2 absorption test due to rapid or variable rates of exchange of 58Co-B|2 for 57Co-Bi2 bound to intrinsic factor. Nucl Med Commun 4:17-23, 1983
417. Briedis D, Mclntyre PA, Judisch, et al: An evaluation of a dual-isotope method for the measurement of vitamin Br2 absorption. J Nucl Med 14:135-141, 1973
418. Donaldson RM, Katz JH: Exchange between free and gastric juice-bound cyanocobalamin. J Clin Invest 42:534-545, 1963
419. Medi-Physics, Inc: Dicopac users guide. Arlington Heights, IL, Medi-Physics. Inc, 1990
420. Howard BY: Safe handling of radioiodinated solutions. J Nucl Med Technol 4:28-30, 1976
421. Croft BY: Safe handling of radioiodine. J Nucl Med 20:362-363, 1979 (letter)
422. Luckett LW, Stotler RE: Radioiodine volatilization from reformulated sodium iodide IJ1I oral solution. J Nucl Med 21:477-479, 1980
423. Carey JE, Swanson DP: Thyroid contamination from airborne 131I. J Nucl Med 20:362, 1979 (letter)
424. Jackson GL, Maclntyre F: Accumulation of radioiodine in staff members. J Nucl Med 20:995, 1979 (letter)
425. Wolfangel RG: Accumulation of radioiodine in staff members. Reply. J Nucl Med 20:995, 1979 (letter)
426. Browning EJ, Banerjee K. Reisinger WE: Airborne concentration of 1-131 in a nuclear medicine laboratory. J Nucl Med 19:1078-1081, 1978
427. Maguire WJ: A precaution for minimizing radiation exposure from iodine vaporization. J Nucl Med Technol 8:90-93, 1980
428. 131I. Radiology 136:767-771, 1980
429. Haney TA, Wedeking P, Morcos N, et al: A therapeutic and diagnostic °'I capsule formulation with minimal volatility and maximum bioavailability. J Nucl Med 22:P74, 1981 (abstr)
430. Grossman LW, Williams CC: Chilling-An effective way of reducing volatility of therapeutic iodine solutions. J Nucl Med 21:P93, 1980 (abstr)
431. Dansereau R, Dansereau R: A new coated-bed dosaged form of sodium iodide 1-131. J Nucl Med 30:886, 1989 (abstr)
432. Herbert V: Detection of malabsorption of vitamin BU due to gastric or intestinal dysfunction. Semin Nucl Med 2:220-234, 1972
433. Gobuty AH: Clinical radiopharmacy: troubleshooting the Schilling test. ASHP Signal Nov: 5-6, 1979
434. Halpern SE, Nagan PL, Chauncey D, et al: The effect of certain variables on the tumor and tissue distribution of tracers. Part 1: Carrier. Invest Radiol 14:482-492, 1979
435. Hoffer P: Gallium: Mechanisms. J Nucl Med 21:282285, 1980
436. Ongseng F, Goldfarb CR, Finestone H: Axillary lymph node uptake of Technetium-99m-MDP. J Nucl Med 36:1797-1799, 1995
437. Vieras F: Serendipitous lymph node visualization during bone imaging. Clin Nucl Med 11:434, 1986
438. Taillefer R, Robidoux A, Lambert R, et al: Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 36:1758-1765,1995
439. Peller PJ, Ho VB, Kransdorf MJ: Extraosseous Tc-99m MDP uptake: A pathophysiologic approach. Radiographics 13:715-734,1993
440. Gentili A, Miron SD, Adler LP: Review of some common artifacts in nuclear medicine. Clin Nucl Med 19:138-143,1994
441. Patton HS, Millar RG: Accidental skin ulcérations from radioisotopes: Recognition, prevention and treatment. JAMA 143:554,1950
442. Breen SL, Driedger AA: Radiation injury from interstitial injection of Iodine-131-iodocholesterol. J Nucl Med 32:892,1991
443. Piers DA, Beekhuis H: Local radiation dose from extravasal Tl-201. J Nucl Med 28:684,1987 (abstr)
444. European Nuclear Medicine Society: Newsletter 9:487-490,1988
445. Shapiro B, Pillay M, Cox PH: Dosimetric consequences of interstitial extravasation following IV administration of a radiopharmaceutical. Eur J Nucl Med 12:522-523, 1987
446. Hoop B: The infiltrated radiopharmaceutical injection: Risk considerations. J Nucl Med 32:890-891,1991
447. Root TR, Stanley AP: Extravasation, in Allwood M, Wright P (eds): Cytotoxicx Handbook. Oxford, Radcliffe Medical, 1993, pp 77-89
448. Lutzker LG, Ferez LA: Radioactive embolization from upper-extremity thrombophlebitis. J Nucl Med 16:241242,1975
449. Goldberg E, Lieberman C: "Hot spots" in lung scans. J Nucl Med 18:499,1977
450. Preston DF, Greenlaw RH: "Hot spots" in lung scans. J Nucl Med 11:422-425, 1970
451. Natasa B, Ugo F, Igor B: Pulmonary radiation microemboli. J Nucl Med 19:1183,1978
452. Shih WJ, Brandenburg S, Coupai JJ, et al: Hot spot(s) of the lung in technetium-99m albumin colloid liver-spleen scintigraphy: Case report. J Nucl Med Technol 16:61-63,1988
453. Mettler FA, Christie JH: Focal lung uptake of Tc-99m-sulfur colloid. Clin Nucl Med 7:322-323,1982
454. Kowalsky RJ, Perry JR: Liver, gallbladder, spleen and bone marrow, in Baum S (ed): Radiopharmaceuticals in Nuclear Medicine Practice. Norwalk, CT, Appleton & Lange, 1992, pp 271-314
455. Woolman PS, Coutts CT, Mole DR, et al: Sites of deposition of aqueous aerosols: A study of efficiency of delivery systems for lung ventilation imaging in man. Nucl Med Commun 10:171-180,1989
456. Dickenson G, Smaldone GC: Particle deposition and failure of prophylaxis using aerosolized pentamidine. Am Rev Respir Dis 131:A150,1990
457. Wanner A, Brodnan JM, Ferez J, et al: Variability of airway responsiveness to histamine aerosol in normal subjects. Am Rev Respir Dis 131:3-7,1985
458. Ilowite JS, Gorvoy JD, Smaldone GC: Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 136:1445-1449,1987
459. Struttman LG: Product Background Report: UltraVent Radioaerosol Delivery System. St. Louis, Mo, Mallinckrodt Medical Inc, 1987
460. Kowalsky RJ: Stability of xenon-127 in unit dose vial. J Nucl Med Technol 7:222-225,1979
461. Slater DM, Anderson M, Garvie NW: Syringe extractables: Effects on radiopharmaceuticals. Lancet 2:14311432,1983 (letter)
462. Hegge F, Hamilton GW, Larson, et al: Cardiac chamber imaging: A comparison of red blood cells labeled with Tc-99m in vitro and in vivo. J Nucl Med 19:129-134, 1978
463. Thrall JH, Swanson DP: Clinical comparison of cardiac blood pool visualization with technetium-99m red blood cells labeled in vivo and with technetium-99m human serum albumin: Reply. J Nucl Med 20:1214-1215, 1979 (letter)
464. Hladik WB, Nigg KK, Rhodes BA: Drug-induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med 12:184-218,1982
465. Wieseler JF, Gebhard MW, Hung JC, et al: In vivo comparison of anticoagulant citrate dextrose versus heparin for use as an anticoagulant with the UltraTag® red blood cell kit. J Nucl Med Technol 22:178-181, 1994